HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMS 185660

structure in first source

Also Known As:

BMS-185660

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - Taxoids: 2650
        BMS 185660: 2
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclodecanes
        Taxoids: 2650
        BMS 185660: 2

Experts

1.	Golik, J: 1 article (01/2000)
2.	Kadow, J: 1 article (01/2000)
3.	Lee, F Y: 1 article (01/2000)
4.	Rose, W C: 1 article (01/2000)

Related Diseases

1.	Carcinoma (Carcinomatosis) 01/01/2000 - "Also, in the human HCT-116 colon carcinoma model, oral BMS-185660 cured a maximum of seven of eight mice compared with six of seven mice cured with i.v. paclitaxel. "
2.	Neoplasms (Cancer) 01/01/1997 - "In each of the tumor models used, the consistently active, and usually the most active, water-soluble derivative was BMS-185660. " 01/01/1997 - "Based on the evaluations performed in three distal site tumor models, we conclude that BMS-185660 is a water-soluble paclitaxel derivative with preclinical antitumor activity comparable to that of the parent drug." 01/01/2000 - "Against a human ovarian tumor model with developed resistance to cisplatin (A2780/ cDDP), oral BMS-185660 achieved a maximum LCK of 1.8 compared with i.v. paclitaxel, which produced a maximum 2.4 LCK. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Cisplatin (Platino)